It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene therapies.
Haider Warraich was once the only cardiologist for more than 150,000 people in a rural county. Now he’s running an ARPA-H ...
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...
John MacDonald, 73, took part in a clinical trial using gene therapy to extend the lifespan of blood vessels in the heart ...
Live Science on MSNOpinion
From gene therapy breakthroughs to preventable disease outbreaks: The health trends that will shape 2026Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in ...
Scott Pelley, one of the most experienced and awarded journalists today, has been reporting stories for 60 Minutes since 2004. The 2024-25 season is his 21st on the broadcast. Scott has won half of ...
There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University's College of Medicine and the UMass Chan Medical School have achieved ...
For select patients with advanced heart failure (AHF), durable left ventricular assist device (LVAD) therapy can be a life-sustaining option that improves quality of life. Since its introduction a few ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback